相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
Mark G. Lebwohl et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Clinical Goals and Barriers to Effective Psoriasis Care
Bruce E. Strober et al.
DERMATOLOGY AND THERAPY (2019)
Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study
Nikolai Dyrberg Loft et al.
ACTA DERMATO-VENEREOLOGICA (2019)
A detailed analysis of not relevant' responses on the DLQI in psoriasis: potential biases in treatment decisions
F. Rencz et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab
Jeanette Halskou Hesselvig et al.
ACTA DERMATO-VENEREOLOGICA (2018)
Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis
F. Rencz et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Lluis Puig et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis
M. Augustin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis
L. Puig et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients
Michael Abrouk et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatogy Life Quality Index (DLQI): Further Data
M. K. A. Basra et al.
DERMATOLOGY (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis
Hema N. Viswanathan et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory
K. B. Gordon et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis
Dennis A. Revicki et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2014)
Quality of life in psoriasis patients
Matthias Augustin et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2014)
Long-term efficacy of ustekinumab in moderate-to-severe psoriasis
A. B. Kimball et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
M. Lebwohl et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
Richard G. Langley et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
The psychosocial burden of psoriasis
AB Kimball et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2005)
分享论文
